Goldman Sachs
AXSM icon

Goldman Sachs’s Axsome Therapeutics AXSM Stock Holding History

Goldman Sachs’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,200
Closed -$230K – 6330
2025
Q2 		$230K Buy
+2,200
New +$233K ﹤0.01% 5590
2020
Q2 		– Sell
-18,500
Closed -$1.09M – 5194
2020
Q1 		$1.09M Buy
+18,500
New +$1.51M ﹤0.01% 3690

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs's AXSM Position: Q2 2026 in Review

Goldman Sachs reduced its Axsome Therapeutics (AXSM) stake by 46% in Q2 2026, selling an estimated $41.6M and leaving 229,668 shares worth $56.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1701.

Goldman Sachs first reported a position in AXSM in Q4 2015 and has held it in 35 quarters since. The position peaked at $71.2M in Q1 2026. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Goldman Sachs held 229,668 shares of Axsome Therapeutics worth $56.2M as of Q2 2026.
  • Goldman Sachs sold 191,779 Axsome Therapeutics shares in Q2 2026, an estimated $41.6M.
  • Axsome Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #1701 holding.
  • Goldman Sachs first reported a position in Axsome Therapeutics in Q4 2015 and has held it in 35 quarters since.
  • Goldman Sachs's Axsome Therapeutics position peaked at $71.2M in Q1 2026.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.